NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NorthSea Therapeutics has raised $80.0M in total funding. The most recent round was Series C. The last funding was announced in December 2021.
NorthSea Therapeutics's investors include Novo Holdings, Sofinnova Investments, Forbion Capital Partners, Hercules Capital, Ysios Capital.
NorthSea Therapeutics is headquartered in Naarden, The Netherlands.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
NorthSea Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NorthSea Therapeutics — Funding & Investors." VCBacked, December 17, 2021, https://www.vcbacked.co/company/northsea-therapeutics. Accessed August 14, 2026.
VCBacked. (2021). NorthSea Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/northsea-therapeutics
{{cite web |title=NorthSea Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/northsea-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated